Market Newsdesk

Camping World Declares First Quarter Dividend For Stockholders of Record on March 14, 2023 to be paid on March 29, 2023

LINCOLNSHIRE, Ill.–(BUSINESS WIRE)–
Camping World Holdings, Inc. (NYSE: CWH) (the “Company,” “Camping World,” “we,” “us” or “our”), announced today that its Board of Directors declared a regular cash dividend of $0.625 per share on the Company’s Class A Common Stock. Payment is expected to be made on March 29, 2023, to stockholders of record at the close of business on March 14, 2023.

Marcus Lemonis, Chairman and Chief Executive Officer stated, “Our organization is taking decisive action on SG&A, capex, and underperforming assets, so that we have the flexibility to continue to make accretive dealership acquisitions and return capital to shareholders through the dividend.”

Future declarations of quarterly dividends are subject to the determination and discretion of Camping World’s Board of Directors based on its consideration of various factors, including the Company’s results of operations, financial condition, level of indebtedness, anticipated capital requirements, contractual restrictions, restrictions in its debt agreements, restrictions under applicable law, receipt of excess or surplus of tax distributions received from CWGS Enterprises, LLC, its business prospects and other factors that Camping World’s Board of Directors may deem relevant.

About Camping World Holdings, Inc.

Camping World Holdings, Inc., headquartered in Lincolnshire, IL, (together with its subsidiaries) is America’s largest retailer of RVs and related products and services. Our vision is to build a long-term legacy business that makes RVing fun and easy, and our Camping World and Good Sam brands have been serving RV consumers since 1966. We strive to build long-term value for our customers, employees, and shareholders by combining a unique and comprehensive assortment of RV products and services with a national network of RV dealerships, service centers and customer support centers along with the industry’s most extensive online presence and a highly trained and knowledgeable team of associates serving our customers, the RV lifestyle, and the communities in which we operate. We also believe that our Good Sam organization and family of programs and services uniquely enables us to connect with our customers as stewards of the RV enthusiast community and the RV lifestyle. With RV Sales and service locations in 42 states, Camping World has grown to become the prime destination for everything RV. For more information, visit www.CampingWorld.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 concerning Camping World and other matters. All statements other than statements of historical facts contained in this press release may be forward-looking statements. Statements regarding our future results of operations and financial position, anticipated cost reduction initiatives, including the reduction of SG&A expenses and capital expenditures and elimination of or reduction of underperforming assets, anticipated cost savings from cost reduction initiatives, future financial results, future acquisitions, capital return strategy, and expected dividend payments are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as ‘‘may,’’ ‘‘will,’’ ‘‘should,’’ ‘‘expects,’’ ‘‘plans,’’ ‘‘anticipates,’’ ‘‘could,’’ ‘‘intends,’’ ‘‘targets,’’ ‘‘projects,’’ ‘‘contemplates,’’ ‘‘believes,’’ ‘‘estimates,’’ ‘‘predicts,’’ ‘‘potential’’ or ‘‘continue’’ or the negative of these terms or other similar expressions. The forward-looking statements in this press release are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. You should carefully consider the risks and uncertainties that affect our business, including the important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K filed for the year ended December 31, 2022 and our other reports filed with the SEC. These forward-looking statements speak only as of the date of this communication. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements, whether as a result of any new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our public announcements and filings with the Securities and Exchange Commission.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230228005525/en/

For Camping World Holdings, Inc.

Investors

Brett Andress

[email protected]

Media Outlets

[email protected]

KEYWORDS: Illinois United States North America

INDUSTRY KEYWORDS: Family Sports General Automotive Consumer Vacation Specialty Retail Other Travel Recreational Vehicles Transportation Outdoors Travel Hunting Online Retail Automotive Other Consumer Discount/Variety Fishing Department Stores Women Seniors Men

MEDIA:

Logo

Stratasys Signs Agreement with Ricoh USA, Inc. for Print-On-Demand Medical Models

Collaboration increases access to 3D-printed anatomic models for hospitals and clinics.

EDEN PRAIRIE, Minn. & REHOVOT, Israel–(BUSINESS WIRE)–Stratasys Ltd. (NASDAQ: SSYS), a leader in polymer 3D printing, announced today it has signed an agreement with Ricoh USA, Inc. to provide on-demand 3D-printed anatomic models for clinical settings. Stratasys’ Patient-Specific 3D Solutions combines 3D printing technology from Stratasys, the cloud-based Segmentation-as-a-Service^TM solution from Axial3D, and precision additive manufacturing services from Ricoh into one convenient solution. The new service builds on an existing relationship between Ricoh 3D for Healthcare and Stratasys to expand access to 3D-printed medical models.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230228005490/en/

Anatomic 3D-printed models are realistic, specific visualizations of a patient’s anatomy, allowing practitioners to plan and practice complex surgeries and improve communication between medical staff, the patient, and their families. Digital Anatomy™ technology from Stratasys even enables these models to be biomechanically realistic, with the feel and responsiveness of real bone and tissue.

While this method of surgical planning offers benefits to patients and care teams, the need for up-front capital investments and on-site 3D printing technical expertise are significant barriers to its adoption. This new service removes those barriers to expand access to more hospitals and clinics, and ultimately contributes to better outcomes.

The new offering gives clinicians and patients increased access to patient-specific 3D-printed models for pre-operative surgical planning, diagnostic use, and surgical education. Using these models, clinicians can demonstrate treatment decisions to patients and surgical staff. Surgical planning with patient-specific 3D models can improve clinical outcomes and drive significant savings through improved productivity.

With the new collaboration, customers can upload medical files to a secure cloud-based service where Axial3D’s artificial intelligence-powered software automatically converts medical scans into 3D printable files. The files are then printed on Stratasys 3D printers at Ricoh’s ISO 13485 certified facility, with the models shipped directly to the care facility. These changes allow a process that normally takes weeks to be completed in days, without the need for onsite 3D printing equipment or additive manufacturing technical expertise.

“With the advancement in imaging techniques and 3D-printing technology, we are seeing an increased demand for personalized solutions,” said Ben Klein, general manager of Patient-Specific Solutions for Stratasys. “We offer a simplified and scalable, comprehensive solution that increases access to patient-specific 3D-printed models in a fraction of time to help deliver highly personalized treatment and care.”

The partnership builds on the companies’ proven history of successful collaboration. Ricoh’s quality control processes, manufacturing expertise, and healthcare experience provide the specialized production capacity necessary to scale access to models produced using Stratasys’ technology.

“We are providing an opportunity for healthcare providers to access state-of-the-art, precision additive manufacturing without absorbing the overhead costs,” Gary Turner, managing director of Additive Manufacturing, Ricoh USA. “Offering this solution means democratized, wider access to patient-specific 3D-printed models that can improve outcomes and the patient experience, while also enhancing physician education and training.”

The service will be available starting March 3, 2023. For more information, please visit the Axial3D and Stratasys websites. Axial3D (booth 2859), Stratasys (booth 2859), and Ricoh (booth 2659) will exhibit and further discuss their shared ambition to increase access to patient-specific 3D printed models at the American Academy of Orthopedic Surgeons Annual Meeting and tradeshow in Las Vegas from March 7 to 11, 2023.

About Ricoh

Ricoh is empowering digital workplaces using innovative technologies and services that enable individuals to work smarter from anywhere. With cultivated knowledge and organizational capabilities nurtured over its 85-year history, Ricoh is a leading provider of digital services, information management, and print and imaging solutions designed to support digital transformation and optimize business performance.

Headquartered in Tokyo, Ricoh Group has major operations throughout the world and its products and services now reach customers in approximately 200 countries and regions. In the financial year ended March 2022, Ricoh Group had worldwide sales of 1,758 billion yen (approx. 14.5 billion USD).

For further information, please visit www.ricoh.com

About Stratasys

Stratasys is leading the global shift to additive manufacturing with innovative 3D printing solutions for industries such as aerospace, automotive, consumer products and healthcare. Through smart and connected 3D printers, polymer materials, a software ecosystem, and parts on demand, Stratasys solutions deliver competitive advantages at every stage in the product value chain. The world’s leading organizations turn to Stratasys to transform product design, bring agility to manufacturing and supply chains, and improve patient care.

To learn more about Stratasys, visit www.stratasys.com, the Stratasys blog, Twitter, LinkedIn, or Facebook. Stratasys reserves the right to utilize any of the foregoing social media platforms, including the company’s websites, to share material, non-public information pursuant to the SEC’s Regulation FD. To the extent necessary and mandated by applicable law, Stratasys will also include such information in its public disclosure filings.

Stratasys, and Digital Anatomy are trademarks or registered trademarks of StratasysLtd. and/or its affiliates. All other trademarks are the property of their respective owners, and Stratasys assumes no responsibility with regard to the selection, performance, or use of these non-Stratasys products.

Note Regarding Forward-Looking Statement

The statements in this press release regarding Stratasys are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are subject to significant risks and uncertainties, and actual results could differ materially from those projected. There can be no assurance that Stratasys will be able to complete the transaction on the anticipated terms, or at all. Important factors that could cause actual results and developments to differ materially from those anticipated in these forward-looking statements include, among other things, risks and uncertainties related to market conditions, satisfaction of customary closing conditions related to the transaction and the risk factors and other matters referred to under “Risk Factors”, and generally in Stratasys’ Annual Report on Form 20-F for the year ended December 31, 2021 filed with the U.S. Securities and Exchange Commission, or SEC, on February 24, 2022, May 17, 2022, and in other reports that Stratasys furnishes to or files with the SEC from time to time, including, most recently, the report of foreign private issuer on Form 6-K reporting Stratasys’ results for the quarter ended September 30, 2022, furnished to the SEC on November 10, 2022. Readers are urged to carefully review and consider the various disclosures made in Stratasys’ SEC reports, which are designed to advise interested parties of the risks and other factors that may affect its business, financial condition, results of operations and prospects. The forward-looking statements in this release speak only as of this date, and Stratasys disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230228005490/en/

Stratasys Corporate:

North America

Chris Reese

[email protected]

+1 952 262 1657

Investor Relations

Yonah Lloyd

[email protected]

+972 74 745 4919

PR Europe, Middle East, and Africa

Jonathan Wake / Miguel Afonso, Incus Media

[email protected]

+44 1737 215200

Israel

Rosa Coblens

[email protected]

+972 7474 54903

Ricoh:

Justine Mrsich

[email protected]

+1 909 606 2173

KEYWORDS: United States North America Israel Middle East Minnesota

INDUSTRY KEYWORDS: Software Hardware Electronic Design Automation Technology Hospitals Other Manufacturing Artificial Intelligence Surgery Engineering Chemicals/Plastics Other Technology Health Manufacturing

MEDIA:

Logo

Photo

Anatomic 3D-printed models allow medical staff to practice and plan for surgeries. (Photo: Business Wire)

Photo

Anatomic 3D-printed models allow medical staff to practice and plan for surgeries. (Photo: Business Wire)

Cybin Announces Positive Data from its CYB003 Phase 1/2a Trial and Provides Update on its CYB004 Development Program

– CYB003 Phase 1/2a interim data demonstrate rapid and short-acting effects; robust psychedelic effects at low doses; positive safety and tolerability profile; top-line efficacy data expected late Q3 2023 –

– Initial findings from Phase 1 CYB004-E study suggest IV DMT was well-tolerated; study design expanded to accelerate first-in-human dosing of CYB004 –

– Company to host R&D Day webcast today, February 28, 2023, at 10:00am ET –

This news release constitutes a “designated news release” for the purposes of Cybin’s prospectus supplement dated August 8, 2022 to its short form base shelf prospectus dated July 5, 2021

TORONTO–(BUSINESS WIRE)–Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics^® today announced significant progress updates for its two lead clinical development programs: CYB003, its proprietary deuterated psilocybin analog for the potential treatment of Major Depressive Disorder and CYB004, its proprietary deuterated N,N-dimethyltryptamine molecule being developed for the potential treatment of Generalized Anxiety Disorder. In connection with today’s announcement, Cybin will host an R&D Day today, February 28, 2023, at 10:00am ET. To register for the virtual event, click here.

Interim findings from the Company’s ongoing Phase 1/2a clinical trial evaluating CYB003 demonstrated positive observations, including a rapid and short-acting psychedelic response in participants. Participants received single oral doses of CYB003 at 1 milligram (“mg”), 3mg, 8mg, and 10mg, respectively, and all doses were well-tolerated with no serious adverse events reported. Most notably, participants reported meaningful and robust psychedelic effects at the 8mg and 10mg doses, confirming a complete mystical experience was achieved. These interim findings demonstrate that CYB003 was rapid and short acting, had low variability in plasma levels, and reached a psychedelic effect at low doses, while maintaining a safe and well-tolerated therapeutic profile. As of the date of this press release, Phase 1 dosing has been completed and the Phase 2a portion of the trial has commenced. Cybin expects to report top-line results from the completed Phase 1/2a clinical trial in late third quarter of calendar year 2023.

“It is incredibly gratifying that our findings from the interim readout of the CYB003 Phase 1/2a clinical trial align with the results observed in preclinical studies. Robust psychedelic effects were observed at low doses, absorption was rapid with low variability, and effects were short lasting – all desired outcomes. These findings give us confidence in the potential efficacy of the underlying active agent, which may ultimately reduce symptoms of depression after just one or two doses. This would be a remarkable improvement over chronic treatments that are available today,” said Doug Drysdale, Chief Executive Officer of Cybin. “We are encouraged by the progress made in advancing our CYB003 molecule and look forward to continuing the momentum to advance this program through clinical development to bring this important treatment option to people who suffer from depression as quickly as possible.”

The Company today also provided an update on its Phase 1 CYB004-E trial evaluating intravenous N,N-dimethyltryptamine (“IV DMT”) in healthy volunteers. Per a protocol amendment to the initial trial design, Cybin has established a three-part study to include Part A (IV DMT infusion), Part B (IV DMT bolus + infusion) and Part C (CYB004) in healthy volunteers, which will allow the Company to initiate first-in-human dosing of CYB004 sooner than initially planned. Data from the new Parts B and C of the trial will serve to build a more robust pharmacokinetic (“PK”) and pharmacodynamic (“PD”) model to optimize dose selection and formulation development for future clinical studies. The Company confirmed today that Part A of the trial evaluating DMT IV in participants is now complete, and IV DMT at the evaluated dose ranges was demonstrated to be safe and well-tolerated. As of the date of this press release, the Phase 1 CYB004-E trial has dosed 40 participants in Part A and dosing has commenced in Part B. Dosing of CYB004 in Part C is expected to begin in early Q2 2023, following the completion of Part B. Cybin expects to report top-line results from the completed Phase 1 CYB004-E clinical trial in the third quarter of calendar year 2023.

“Our CYB004 program has made significant progress marked by confirmatory results from Part A of the Phase 1 CYB004-E trial and the acceleration of first-in-human dosing of CYB004,” continued Drysdale. “Recent protocol amendments will allow us to further evaluate CYB004 and demonstrate the advantages of deuteration on PK and PD parameters​. We see the potential for short duration treatments, which could truly transform the treatment paradigm and outcomes for patients. As well, we believe that deuteration may support less invasive and more convenient dosing methods for providers and patients.”

R&D Day to be held today February 28, 2023, at 10:00 a.m. ET.

Cybin’s leadership team is hosting a virtual R&D Day event today, featuring key opinion leader Dr. Maurizio Fava, Psychiatrist-in-Chief of Massachusetts General Hospital (“MGH”), Vice Chair of the MGH Executive Committee on Research, Executive Director of the Clinical Trials Network and Institute at MGH, Associate Dean for clinical and translational research, and the Slater Family Professor of Psychiatry at Harvard Medical School. The Company will provide further information on the interim readout from its ongoing CYB003 Phase 1/2a trial and additional updates on its CYB004 program. Click here to register for the event.

About Cybin

Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. The Company is focused on progressing Psychedelics to Therapeutics by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders.

Cautionary Notes and Forward-Looking Statements

Certain statements in this news release relating to the Company are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding; the anticipated results and potential of CYB003 and the Company’s CYB003 Phase 1/2a trial; the Company’s plan to report top-line results from the complete CYB003 Phase 1/2a clinical trial; the Company’s plan to report top-line results from the complete Phase 1 CYB004-E clinical trial; statements regarding the Company’s Phase 1 DMT clinical study for CYB004-E, anticipated results and the impact of this study on future clinical trials; the Company’s clinical development program evaluating CYB004 and timeline for dosing healthy volunteers; and the Company’s plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health conditions.

These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: implications of the COVID-19 pandemic on the Company’s operations; fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the psychedelics market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; and the risk factors set out in each of the Company’s management’s discussion and analysis for the three and nine month periods ended December 31, 2022, the Company’s annual information form for the year ended March 31, 2022, and the Company’s listing statement dated November 9, 2020 which are available under the Company’s profile on www.sedar.com and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov. Although the forward- looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

Cybin makes no medical, treatment or health benefit claims about Cybin’s proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. Cybin has not conducted clinical trials for the use of its proposed products. Any references to quality, consistency, efficacy and safety of potential products do not imply that Cybin verified such in clinical trials or that Cybin will complete such trials. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybin’s performance and operations.

Neither the Neo Exchange Inc. nor the NYSE American LLC stock exchange have approved or disapproved the contents of this news release and are not responsible for the adequacy and accuracy of the contents herein.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230228005438/en/

Investors & Media:

Leah Gibson

Vice President, Investor Relations & Strategic Communications

Cybin Inc.

[email protected] – or – [email protected]

Gabriel Fahel

Chief Legal Officer

Cybin Inc.

1-866-292-460

KEYWORDS: North America Canada

INDUSTRY KEYWORDS: Biotechnology Alternative Medicine Health Mental Health

MEDIA:

Logo

The Real Brokerage to Host Fourth Quarter and Full Year 2022 Earnings Conference Call

TORONTO & NEW YORK–(BUSINESS WIRE)–
The Real Brokerage Inc. (TSX: REAX) (NASDAQ: REAX), the fastest growing publicly traded real estate brokerage, today announced that it will release its fourth quarter and full year 2022 financial results before market open on Thursday, March 16, 2023.

The company will subsequently hold a conference call to discuss operating and financial results for the quarter and full year on Thursday, March 16, 2023 at 11:00 AM EST.

Conference Call Details:

Date:		Thursday, March 16, 2023
Time:		11:00 a.m. EST
Dial-in Number:		North American Toll Free: 888-506-0062
		International: 973-528-0011
Access Code:		937975
Webcast:		https://www.webcaster4.com/Webcast/Page/2699/47478
Replay Number:		North American Toll Free: 877-481-4010
		International: 919-882-2331
Passcode:		47478
Replay Link:		https://www.webcaster4.com/Webcast/Page/2699/47478

Forward-Looking Information

This press release contains forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking information is often, but not always, identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “likely” and “intend” and statements that an event or result “may”, “will”, “should”, “could” or “might” occur or be achieved and other similar expressions. These statements reflect management’s current beliefs and are based on information currently available to management as at the date hereof. Forward-looking information in this press release includes, without limiting the foregoing, information relating to Real’s fourth quarter and full year 2022 earnings call, the release of the financial results and the business and strategic plans of Real.

Forward-looking information is based on assumptions that may prove to be incorrect, including but not limited to Real’s business objectives, expected growth, results of operations, performance, business projects and opportunities and financial results. Real considers these assumptions to be reasonable in the circumstances. However, forward-looking information is subject to known and unknown risks, uncertainties and other factors that could cause actual results, performance or achievements to differ materially from those expressed or implied in the forward-looking information. These factors should be carefully considered and readers should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, Real cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this press release, and Real assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law.

About Real

The Real Brokerage Inc. is revolutionizing the residential real estate industry by pairing best-in-class technology with the trusted guidance of the agent-led experience. We provide a digital brokerage platform for agents, while working to build a better end-to-end home buying experience for consumers. The company was founded in 2014 and serves 45 states, D.C., and three Canadian provinces with over 9,000 agents. Additional information can be found on our website at www.onereal.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230228005290/en/

For additional information, please contact:

Jason Lee

Vice President, Capital Markets & Investor Relations

[email protected]

908.280.2515

For media inquiries, please contact:

Elisabeth Warrick

Director, Communications

[email protected]

201.564.4221

KEYWORDS: United States North America Canada New York

INDUSTRY KEYWORDS: Professional Services Technology Residential Building & Real Estate Other Technology Finance Construction & Property

MEDIA:

Logo

Syros to Participate in Upcoming Investor Conferences in March

CAMBRIDGE, Mass.–(BUSINESS WIRE)–
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a panel discussion and present a corporate overview at two upcoming investor conferences in March. Management will also be available for one-on-one meetings. Details are as follows:

Cowen 43rd Annual Health Care Conference

Date: Tuesday, March 7

Panel Title: Novel Oncology Targets

Panel Time: 9:10 a.m. ET

Location: Boston Marriott Copley Place, 110 Huntington Ave, Boston, MA

Oppenheimer 32nd Annual Healthcare Conference

Date: Monday, March 13

Presentation Time: 8:00 a.m. ET

Location: Virtual

To access the webcasts and subsequent archived recording of each event, please visit the Investors & Media section of the Syros website at www.syros.com. An archived replay of each webcast will be available for approximately 30 days following each presentation.

About Syros Pharmaceuticals

Syros is committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies. Driven by the motivation to help patients with blood disorders that have largely eluded other targeted approaches, Syros is advancing a robust late-stage clinical pipeline, including tamibarotene, a first-in-class oral selective RARα agonist in patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia with RARA gene overexpression, and SY-2101, a novel oral form of arsenic trioxide in patients with acute promyelocytic leukemia. Syros is also seeking partnerships for SY-5609, a highly selective and potent CDK7 inhibitor in clinical development for the treatment of select solid tumors, and multiple preclinical programs in oncology and monogenic diseases. For more information, visit www.syros.com and follow us on Twitter (@SyrosPharma) and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230228005027/en/

Syros Contact

Karen Hunady

Director of Corporate Communications & Investor Relations

1-857-327-7321

[email protected]

Media Contact

Brittany Leigh, Ph.D.

LifeSci Communications, LLC

+1-813-767-7801

[email protected]

Investor Contact

Hannah Deresiewicz

Stern Investor Relations, Inc.

212-362-1200

[email protected]

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: Biotechnology Pharmaceutical Health Oncology

MEDIA:

Logo

VX4000 from voxeljet 3D prints casting cores for all-electric Cadillac CELESTIQ

• US-based company Tooling & Equipment International (TEI) expands additive manufacturing capacity with third VX4000 3D sand printer
• As a supplier to General Motors, TEI is using the world’s largest 3D sand printer to produce cast cores for the series production of large-format, weight-saving structural components for the Cadillac CELESTIQ
• Each VX4000 prints hundreds of inner cores for several vehicle sets in just one night: making short delivery times for weight and design-optimized components possible

FRIEDBERG, Germany–(BUSINESS WIRE)–
voxeljet AG (NASDAQ: VJET) (the “Company”, “voxeljet”, or “we”), a provider of high-speed, large-format 3D printers and on-demand parts services to industrial and commercial customers and Tooling & Equipment International (TEI), one of the largest users of 3D sand printing in the US, expand their collaboration: TEI has purchased its third VX4000 3D printer.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230228005066/en/

As a supplier to General Motors, TEI is using the world’s largest 3D sand printer to produce cast cores for the series production of large-format, weight-saving structural components for the Cadillac CELESTIQ. By implementing 3D printing in the development and construction of the components, OEM manufacturers can realize completely new, function-optimized designs. Suppliers benefit from the fast and flexible integration of 3D printed cores into existing production lines.

TEI, an expert in highly complex castings for the engineering and manufacturing industry, has been working with voxeljet since 2018. What started with a three-year volume contract of over 500,000 liters of 3D-printed sand turned into a success story for both companies. TEI is the only company in the US to own three of voxeljet’s VX4000 3D printers, which are among the world’s largest 3D sand printers with a build volume of 4 x 2 x 1 meters. With its third VX4000, TEI has now expanded its additive manufacturing capacity to up to 2.5 million liters per year. This enables the US company to implement further technically demanding projects such as the series production of lightweight components for the underbody structure of the all-electric Cadillac CELESTIQ.

Each casting replaces up to 40 components

The novel underbody structure consists of six large precision sand-cast aluminum parts. In order to realize the complex structures as economically and lightly as possible, TEI uses additive manufacturing in production for all inner cores. This allows stiffening features to be incorporated into the hollow sections, which is not economically feasible with conventional manufacturing. A total of 51 additively manufactured sand cores are used in the production of each vehicle underbody. TEI prints these using the VX4000 printers, each of which prints hundreds of inner cores for several vehicle sets in just one night. After printing, the cores are smoothed, coated with a fireproof coating, placed in sand molds and finally cast using a low-pressure filling process. Each of the six castings reduces the number of parts by 30 to 40 components compared to a typical stamped construction. As each structural part has fully machined interfaces, the six castings can be assembled precisely and very tight tolerances can be maintained for assembly fabrication.

Short delivery times for weight and design-optimized lightweight components

Large-format mold and core printing on the VX4000 3D printers makes production leaner and therefore faster and more economical compared to conventional manufacturing. Significantly fewer components need to be produced, which simplifies and speeds up assembly work. “By eliminating tools and taking advantage of the large build volume of the VX4000 printers, we can significantly reduce delivery times and produce lightweight components with optimized topologies. This would not be possible in the conventional way,” explains Oliver Johnson, President of TEI. In addition, 3D sand printing makes completely new designs and lightweight structures possible. This results in geometrically optimized parts, which are very important for the automotive and aerospace industries. What is important for the implementation at suppliers: New function-optimized designs can be realized quickly and flexibly with the VX4000 3D printers and printed cores can be easily integrated into an existing production.

“We are pleased to have TEI as a strong partner and user of sand 3D printing in the US. The purchase of the third VX4000 printer builds on previous system installations at TEI’s corporate site in Livonia, Michigan, and enables the company to grow rapidly and deliver unique projects like this,” said Michael Dougherty, Managing Director at voxeljet America Inc. “Together, we will further establish additive manufacturing technology in industrial manufacturing and intensify our collaboration. We are proud to support the company with our unique 3D printing technology and to show once again that our printed casting technology is entering production and enabling unprecedented designs.

About voxeljet

voxeljet is a leading provider of high-speed, large-format 3D printers and on-demand parts services to industrial and commercial customers. The Company’s 3D printers employ a powder binding, additive manufacturing technology to produce parts using various material sets, which consist of particulate materials and proprietary chemical binding agents. The Company provides its 3D printers and on-demand parts services to industrial and commercial customers serving the automotive, aerospace, film and entertainment, art and architecture, engineering and consumer product end markets. For more information, visit http://www.voxeljet.de/en/.

About TEI:

TEI is a global leader in the design, engineering and manufacturing of prototype, pre-production and mass production equipment for the casting industry. TEI products are the highest quality and are backed by a reputation for innovation, design excellence, and precise first-run performance. TEI is a full service, vertically integrated supplier offering a complete range of services in Engineering, Tooling, Casting, Machining and Inspection complete on one site. This approach delivers TEI and its customers’ fundamental advantages in terms of timing, confidentiality, and quality.

Cautionary Statement on Forward-Looking Statements

This press release contains forward-looking statements concerning our business, operations and financial performance. Any statements that are not of historical facts may be deemed to be forward-looking statements. You can identify these forward-looking statements by words such as ‘‘believes,’’ ‘‘estimates,’’ ‘‘anticipates,’’ ‘‘expects,’’ ‘‘projects,’’ ‘‘plans,’’ ‘‘intends,’’ ‘‘may,’’ ‘‘could,’’ ‘‘might,’’ ‘‘will,’’ ‘‘should,’’ ‘‘aims,’’ or other similar expressions that convey uncertainty of future events or outcomes. Forward-looking statements include statements regarding our intentions, beliefs, assumptions, projections, outlook, analyses or current expectations concerning, among other things, the projected timing and successful completion of the sale-leaseback transaction, our results of operations, financial condition and business outlook, the industry in which we operate and the trends that may affect the industry or us. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that forward-looking statements are not guarantees of future performance. All of our forward-looking statements are subject to known and unknown risks, uncertainties and other factors that are in some cases beyond our control and that may cause our actual results to differ materially from our expectations, including those risks identified under the caption “Risk Factors” in the Company’s Annual Report on Form 20-F and in other reports the Company files with the U.S. Securities and Exchange Commission. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements for any reason after the date of this press release whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230228005066/en/

Investors and Media

Johannes Pesch

Director Investor Relations and Business Development

[email protected]

Office: +49 821 7483172

Mobile: +49 176 45398316

KEYWORDS: Germany Europe

INDUSTRY KEYWORDS: Engineering Chemicals/Plastics Automotive Manufacturing Technology Aerospace Manufacturing Hardware

MEDIA:

Logo

Photo

Cadillac CELESTIQ; Image source: General Motors / Cadillac

Photo

Tooling & Equipment International (TEI), one of the largest US users of 3D sand printing, is expanding its additive manufacturing capacity with the third VX4000 3D printer from voxeljet. (Photo: Business Wire)

Photo

At TEI’s Livonia site in Michigan, the VX4000 prints casting cores for the series production of large-format structural components for the novel underbody design of the all-electric Cadillac CELESTIQ. (Photo: Business Wire)

VIQ Solutions Partners with Seven of the Top Ten U.S. Insurance Companies to Increase Productivity and Expedite Access to Documentation Using AI-Powered Technologies

PHOENIX, Ariz.–(BUSINESS WIRE)–
VIQ Solutions Inc. (“VIQ”, “VIQ Solutions” or the “Company”) (TSX and Nasdaq: VQS), a global provider of secure, AI-driven, digital voice and video capture technology and transcription services, today announces a partnership with another top ten U.S. insurance company, increasing its partnerships to seven of the top ten, as the Company continues to drive change in the Insurance documentation market.

Fortune 500 Insurers are moving towards a more strategic and modern approach to documentation. There is growing demand to leverage advanced automation tools which are a critical factor to increase capacity, reduce inefficiencies and improve compliance. VIQ offers the insurance industry a unique combination of innovative technology, industry domain knowledge and services expertise that speeds the documentation process using powerful workflow automation and secure AI-powered technology.

VIQ technology is driving change in the insurance industry with now seven of the top ten U.S. insurance companies using the Company’s technology and services. This impressive client list uniquely positions VIQ with the ability to apply vertical-specific content enhancing the AI (Artificial Intelligence) engine to deliver improved documentation using a multitude of speech-to-text engines — both propriety and open source — to build customized intellectual property. VIQ’s AI technology culls deep industry content to deliver accurate, diarized documentation with customized formatting that is focused on the specific requirements of insurance providers.

“We are pleased to partner with one of the largest insurance companies in the US to provide recorded claims transcription,” said Susan Sumner, President and Chief Operating Officer, VIQ Solutions. “The growing demand for documentation and compliance is fueling growth opportunities for our platform and services because of our ability to scale and deliver highly complex documentation while adhering to rigorous security requirements.”

As the appetite for digitalization of recorded events increases, technology is required to keep pace with the amount of evidentiary content created. Committed to helping insurers speed documentation, VIQ’s AI-based speech-to-text technology increases efficiency, decreases turnaround time and yields higher transcription accuracy.

About VIQ Solutions

VIQ Solutions is a global provider of secure, AI-driven, digital voice and video capture technology and transcription services. VIQ offers a seamless, comprehensive solution suite that delivers intelligent automation, enhanced with human review, to drive transformation in the way content is captured, secured, and repurposed into actionable information. The cyber-secure, AI technology and services platform are implemented in the most rigid security environments including criminal justice, legal, insurance, government, corporate finance, media, and transcription service provider markets, enabling them to improve the quality and accessibility of evidence, to easily identify predictive insights and to achieve digital transformation faster and at a lower cost.

Forward-Looking Statements

Certain statements included in this news release constitute forward-looking statements or forward-looking information (“forward-looking statements”) under applicable securities legislation. Such forward-looking statements are provided for the purpose of providing information about management’s current expectations and plans relating to the future. Readers are cautioned that reliance on such information may not be appropriate for other purposes.

Forward-looking statements typically contain statements with words such as “anticipate”, “believe”, “expect”, “plan”, “intend”, “estimate”, “propose”, “project” or similar words suggesting future outcomes or statements regarding an outlook. Forward-looking statements in this news release include, but are not limited to, those statements with respect to the benefits of VIQ’s platform and services, including the benefits VIQ offers to insurance companies. Forward-looking statements are based on several factors and assumptions which have been used to develop such statements and information, but which may prove to be incorrect. Although VIQ believes that the expectations reflected in such forward-looking statements are reasonable, undue reliance should not be placed on forward-looking statements because VIQ can give no assurance that such expectations will prove to be correct. In addition to other factors and assumptions which may be identified in this news release, assumptions have been made regarding, among other things, the Company’s strategy and objectives. Readers are cautioned that the foregoing list is not exhaustive of all factors and assumptions that have been used.

Forward-looking statements are necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by the Company as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking statements, including but not limited to the factors described in greater detail in the “Risk Factors” section of the Company’s annual information form dated March 31, 2022 and in the Company’s other materials filed with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission from time to time, available at www.sedar.com and www.sec.gov, respectively. These factors are not intended to represent a complete list of the factors that could affect the Company; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company expressly disclaims any obligation to update or alter any forward-looking statements, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230228005024/en/

Media:

Laura Haggard, Chief Marketing Officer, VIQ Solutions

Email: [email protected]

For more information about VIQ, please visit viqsolutions.com.

KEYWORDS: Arizona United States North America

INDUSTRY KEYWORDS: Technology Professional Services Publishing Security Advertising Telecommunications Communications Software Audio/Video Networks Hardware Insurance Human Resources Data Management Consumer Electronics Consulting Artificial Intelligence

MEDIA:

Logo

BeautyHealth to Acquire SkinStylus^®, FDA-Cleared Microneedling Device

Acquisition is a strategic step in portfolio build-up and BeautyHealth long-term vision

LONG BEACH, Calif.–(BUSINESS WIRE)–
The Beauty Health Company (NASDAQ: SKIN), home to flagship brand Hydrafacial^TM, today announced a definitive agreement to acquire SkinStylus^®, an FDA-cleared microneedling device. The agreement represents a key step forward in BeautyHealth’s portfolio build-up strategy and ultimately its vision to become the world’s leading beauty, health and wellness platform, fueled by a community of engaged providers, estheticians and consumers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230228005649/en/

Expected to reach $1 billion U.S. market size by 2030, microneedling is highly complementary to a Hydrafacial treatment and one of the most common co-treatments offered by providers. Often, a Hydrafacial is recommended as a pre-treatment to microneedling to ensure the skin is prepped and in an optimal state.

“Our long-held vision for BeautyHealth is to build an interconnected platform of brands and services that answer the booming consumer demand for seamless access to beauty health experiences and that support our community of estheticians and providers in delivering amazing services,” said BeautyHealth President and Chief Executive Officer Andrew Stanleick. “SkinStylus is a best-in-class microneedling device and, as an esthetician-founded brand, is grounded in real world insights from the treatment room. We are excited to roll out SkinStylus broadly to our Hydrafacial Nation.”

Microneedling is a non-surgical procedure performed by qualified providers using an array of tiny needles to create microscopic punctures in the skin to stimulate the body’s natural wound response, which is associated with the creation of new collagen and, with that, smoother, firmer and more even-toned skin.

“Microneedling is an exciting advancement in aesthetics that offers a minimally invasive treatment option with little downtime to improve the overall appearance of skin. It is the most requested treatment option from the tens of thousands of providers we work with around the world,” said BeautyHealth Chief Medical Officer Dr. Jwala Karnik. “Having carefully studied the category, we believe SkinStylus is new, better and different to anything else on the market. We are pleased to add SkinStylus to our portfolio and to build on our science-backed treatment offerings.”

Co-invented by a team of skincare and aesthetics professionals, the SkinStylus microneedling device is categorized by the FDA as a class II Medical Device and is cleared as clinically proven to improve the appearance of surgical or traumatic hypertrophic scars on the abdomen in adults aged 22 years and older. In time, BeautyHealth intends to seek FDA clearance for additional indications and regulatory approvals in other markets outside of the U.S.

Upon successful integration of SkinStylus into the BeautyHealth portfolio, the Company expects upside from the acquisition in 2024 and beyond.

About The Beauty Health Company

The Beauty Health Company (NASDAQ: SKIN) is a global category-creating company delivering beauty health experiences that help consumers reinvent their relationship with their skin, bodies and self-confidence. Our flagship brand Hydrafacial^TM, created the category of hydradermabrasion by using a patented vortex-fusion delivery system to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Hydrafacial provides a non-invasive and approachable skincare experience. Together, with our powerful community of aestheticians, consumers and partners, we are personalizing skin care solutions for all ages, genders, skin tones, and skin types. Hydrafacial is available in more than 90 countries with an install base of over 25,000 delivery systems providing millions of experiences to consumers each year. Find a local Hydrafacial at https://hydrafacial.com/find-a-provider/. For more information, visit www.beautyhealth.com.

Forward-Looking Statements

Certain statements made in this release are “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements.

These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside The Beauty Health Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements.

Important factors, among others, that may affect actual results or outcomes include The Beauty Health Company’s ability to execute its business plan; the closing of the acquisition of SkinStylus; the successful integration of SkinStylus into The Beauty Health Company; the ability to complement a hydrafacial treatment with microneedling; potential litigation involving The Beauty Health Company; changes in applicable laws or regulations; the possibility that The Beauty Health Company may be adversely affected by other economic, business, and/or competitive factors; and the impact of the continuing COVID-19 pandemic on the Company’s business. The Beauty Health Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230228005649/en/

The One Nine Three Group

Investors: [email protected]

Press: [email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Luxury Medical Devices Women FDA Men Health Cosmetics Consumer Retail

MEDIA:

Logo

Photo

SkinStylus® (Photo: Business Wire)

Alliant Energy Prices Offering of $500 Million of 3.875% Convertible Senior Notes due 2026

MADISON, Wis.–(BUSINESS WIRE)–
Alliant Energy Corporation (NASDAQ: LNT) announced the pricing of its offering of $500 million aggregate principal amount of its 3.875% convertible senior notes due 2026 in a private placement under the Securities Act of 1933, as amended (the “Securities Act”). Alliant Energy also granted each of the initial purchasers of the convertible notes an option to purchase, within a 13-day period from, and including, the date on which the convertible notes are first issued, up to an additional $75 million aggregate principal amount of the convertible notes. The sale of the convertible notes is expected to close on March 2, 2023, subject to customary closing conditions.

Alliant Energy expects that the net proceeds from the convertible notes will be approximately $490.9 million (or $564.6 million if the initial purchasers exercise their option to purchase additional convertible notes in full), after deducting the initial purchasers’ discounts and commissions and offering expenses payable by Alliant Energy. Alliant Energy intends to use the net proceeds from the offering of the convertible notes for general corporate purposes, which may include repayment or refinancing of debt, working capital, construction and acquisition expenditures, investments and repurchases and redemptions of securities.

The convertible notes will be senior unsecured obligations of Alliant Energy, and will mature on March 15, 2026, unless earlier converted or repurchased in accordance with their terms. The convertible notes will bear interest at a fixed rate of 3.875% per year, payable semiannually in arrears on March 15 and September 15 of each year, beginning on September 15, 2023.

Prior to the close of business on the business day immediately preceding December 15, 2025, the convertible notes will be convertible at the option of the holders only under certain conditions.

On or after December 15, 2025, until the close of business on the business day immediately preceding the maturity date, holders of the convertible notes may convert all or any portion of their convertible notes at their option at any time at the conversion rate then in effect, irrespective of these conditions. Alliant Energy will settle conversions of the convertible notes by paying cash up to the aggregate principal amount of the convertible notes to be converted and paying or delivering, as the case may be, cash, shares of its common stock, $0.01 par value per share, or a combination of cash and shares of its common stock, at its election, in respect of the remainder, if any, of its conversion obligation in excess of the aggregate principal amount of the convertible notes being converted.

The conversion rate for the convertible notes will initially be 15.5461 shares of common stock per $1,000 principal amount of convertible notes (equivalent to an initial conversion price of approximately $64.32 per share of common stock). The initial conversion price of the convertible notes represents a premium of approximately 25% over the last reported sale price of Alliant Energy’s common stock on the Nasdaq Global Select Market on February 27, 2023. The conversion rate and the corresponding conversion price will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. Alliant Energy may not redeem the convertible notes prior to the maturity date.

If Alliant Energy undergoes a fundamental change (as defined in the indenture that will govern the convertible notes), subject to certain conditions, holders of the convertible notes may require Alliant Energy to repurchase for cash all or any portion of their convertible notes at a repurchase price equal to 100% of the principal amount of the convertible notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date (as defined in the indenture that will govern the convertible notes). In addition, if certain fundamental changes occur, Alliant Energy may be required, in certain circumstances, to increase the conversion rate for any convertible notes converted in connection with such fundamental changes by a specified number of shares of its common stock.

The offering is being made to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act. Any offers of the convertible notes will be made only by means of a private offering memorandum. None of the convertible notes or any shares of the common stock issuable upon conversion of the convertible notes have been or are expected to be registered under the Securities Act or any state securities laws and, unless so registered, may not be offered or sold in the United States or to U.S. persons except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws.

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor will there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Forward-Looking Statements

Statements contained in this press release that are not of historical fact are forward-looking statements intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified as such because the statements include words such as “may,” anticipate,” “will,” “would,” “expected,” or other words of similar import. Such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those expressed in, or implied by, such statements. Some, but not all, of the risks and uncertainties that could materially affect actual results include, among others:

• the satisfaction of customary closing conditions relating to the convertible notes offering;
• capital market risks; and
• the impact of general economic or industry conditions.

There can be no assurance that the convertible notes offering will be completed on the anticipated terms, or at all. For more information about potential factors that could affect Alliant Energy’s businesses and financial results, please review “Risk Factors” in Alliant Energy’s Annual Report on Form 10-K for the fiscal year ended 2022 filed with the Securities and Exchange Commission (the “SEC”) and in Alliant Energy’s other filings with the SEC. These factors should be considered when evaluating the forward-looking statements, and undue reliance should not be placed on such statements. The forward-looking statements included herein are made as of the date hereof and, except as required by law, Alliant Energy undertakes no obligation to publicly update such statements to reflect subsequent events or circumstances.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230228005877/en/

Media Hotline: (608) 458-4040

Investor Relations: Susan Gille (608) 458-3956

KEYWORDS: Wisconsin United States North America

INDUSTRY KEYWORDS: Energy Other Energy Utilities Oil/Gas

MEDIA:

Logo